leadf
logo-loader
viewJohnson & Johnson
(
NYSE:JNJ
)

Coronavirus: What sets Johnson & Johnson’s vaccine apart from those already in circulation

There is much anticipation for data on the company's candidate even though some competitors have been rolled out in several countries of the world

Johnson & Johnson - Coronavirus: What sets Johnson & Johnson’s vaccine apart from those already in circulation

Johnson & Johnson (NYSE:JNJ) is expected to reveal data from the final phase of clinical trials for its COVID-19 vaccine early next week.

The pharma giant will also announce whether it can meet the delivery targets agreed with countries that have already purchased some supplies.

Its Belgian arm Janssen has developed an inoculation that, unlike those already being rollout by several countries in the world, aims to offer protection with only one dose.

It is currently being tested on 60,000 volunteers across three continents in a study that started in September.

The first batches are hoped to be ready for emergency authorisation early this year, with J&J scaling up capacity to produce 1bn doses each year.

The formulation is developed Janssen’s AdVac technology, which uses a genetically modified version of the common cold virus (adenovirus) so it can no longer replicate in humans and cause disease.

It can remain stable for two years at -20°C and at least three months at 2-8°C, so it’s compatible with standard distribution channel without the need for extra infrastructure.

The competition

The jab presents some similarities with the Oxford University/AstraZeneca PLC (LON:AZN) formulation as they have both been developed with the traditional method.

By providing the body’s defence mechanisms with advanced warning of the virus, the inoculation triggers production of the antibodies required to fight the real thing when it is contracted.

Oxford researchers used the copy of a chimpanzee viral vector based on a weakened version of a common cold virus, because it causes infections in the animals and contains the genetic material of the SARS-CoV-2 virus spike protein, at the basis of COVID-19.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Therefore it can be stored, transported and handled at normal refrigerated conditions (2-8°C) for at least six months and administered within existing healthcare settings.

Moderna’s mRNA-1273, instead, remains stable at the same temperature for 30 days, but needs to be stored at -20° C for a longer duration of up to six months.

Conversely, Pfizer’s jab BNT162b2 not only must be stored at ultra-cold storage, between -60°C and -80°C, at all times.

This is because they are mRNA-based: driving the process is messenger RNA, or mRNA, which plays a fundamental role in human biology by transferring the instructions stored in DNA to make the proteins required in every living cell.

Medicines based on mRNA instruct a patient’s own cells to produce proteins that could prevent, treat or cure disease.

They are the very first vaccines of this kind to ever be used.

"A gamechanger"

“Global vaccine rollouts have disappointed Europe and the US seems poised to reach herd immunity in the fall… J&J’s single-dose coronavirus vaccine could be a gamechanger for vaccine rollouts if it will be at least 80% effective against COVID-19,” Edward Moya, analyst at OANDA, said last week. 

“Expectations are high for good news from J&J… The short-term risks are growing to the outlook, but no one wants to be short ahead of the potential J&J vaccine late-stage trial results.”

Quick facts: Johnson & Johnson

Follow
NYSE:JNJ

Price: 163.81 USD

Market Cap: $431.23 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FTSE up as government keep cap on gas prices with energy market in focus

FTSE 100 jumped back near the 7,000 mark even though government borrowing was higher than expected in August. London’s leading index added 64 points to 6,968 in early trading.   The UK government has decided to keep the cap on how much energy suppliers can charge customers to protect the...

1 hour, 26 minutes ago

3 min read